[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365862-105":59,"doc-detail-365862-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","drug-repositioning-for-pan-cancers-of-the-digestive-system-identification-of-amonafide-and-bx795-as-potential-therapeutics-via-integrative-omics-analysis","Drug repositioning for pan-cancers of the digestive system - Identification of amonafide and BX795 as potential therapeutics via integrative Omics analysis","","Drug repositioning is explored as an approach to improve outcomes for digestive system cancers, including esophageal, gastric, colorectal, pancreatic, hepatocellular, and biliary tract tumors. Using TCGA transcriptomic data covering six cancer types, the study derives shared differentially expressed genes and performs integrative omics analyses. Enrichment highlights common KEGG pathways with cell-cycle involvement, while PPI modeling pinpoints core genes. Connectivity Map screening prioritizes amonafide and BX795, which inhibit CRC (HT-29) and LIHC (HepG2) proliferation and migration and trigger cell-cycle arrest and apoptosis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/drug-repositioning-for-pan-cancers-of-the-digestive-system-identification-of-amonafide-and-bx795-as-potential-therapeutics-via-integrative-omics-analysis/365862/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/drug-repositioning-for-pan-cancers-of-the-digestive-system-identification-of-amonafide-and-bx795-as-potential-therapeutics-via-integrative-omics-analysis/365862.png","ImageObject",300,407,{"name":92,"@type":93},"Angel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What cancers are included in the pan-cancer analysis in this study?","Question",{"text":112,"@type":113},"The study covers six digestive system cancer types: cholangiocarcinoma, colorectal cancer, esophageal carcinoma, liver hepatocellular carcinoma, pancreatic adenocarcinoma, and stomach adenocarcinoma.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were shared molecular targets identified across digestive system cancers?",{"text":117,"@type":113},"Shared differentially expressed genes were derived using TCGA gene expression profiling, followed by integrative omics analyses including functional enrichment and protein-protein interaction network analysis.",{"name":119,"@type":110,"acceptedAnswer":120},"What drugs were highlighted as potential therapeutics, and how were they tested?",{"text":121,"@type":113},"A Connectivity Map analysis prioritized amonafide and BX795. The drugs were validated to inhibit proliferation and migration of CRC (HT-29) and LIHC (HepG2) cells and to induce cell-cycle arrest and apoptosis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},365862,1790200539,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},687207412472,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","OPEN ACCESS  \nCitation: Liu W, Gao J, Ren S, Nashun B, Gao F (2025) Drug repositioning for pan-cancers of the digestive system: Identification of amonafide and BX795 as potential therapeutics via integrative Omics analysis. PLoS One 20(6): e0325700. [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0325700  \nEditor: Xinjun Lu, Sun Yat-Sen University, CHINA  \nReceived: February 10, 2025  \nAccepted: May 15, 2025  \nPublished: June 16, 2025  \nPeer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0325700  \nCopyright: © 2025 Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution,  \nRESEARCH ARTICLE  \nDrug repositioning for pan-cancers of the digestive system: Identification of amonafide and BX795 as potential therapeutics via integrative Omics analysis  \nWeidong Liu1☯, Jiaying Gao2,3☯, Shuqiang Ren1, Buhe Nashun2,3, Fei Gao1*  \n1 Genome Analysis Laboratory of the Ministry of Agriculture and Rural Affairs, Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences, Shenzhen, China, 2 Inner Mongolia Key Laboratory for Molecular Regulation of the Cell, Inner Mongolia University, Hohhot, China, 3 State Key Laboratory of Reproductive Regulation and Breeding of Grassland Livestock, School of Life Sciences, Inner Mongolia University, Hohhot, China  \n☯ These authors contributed equally to this work.  \n* [flys828@gmail.com](flys828@gmail.com) (FG)  \nAbstract  \nBackground  \nDigestive system cancers, including esophageal, gastric, colorectal, pancreatic, hepatocellular, and biliary tract cancers, constitute a major global health challenge. Despite therapeutic advancements, prognosis remains poor, highlighting the urgent need for novel treatment strategies. We hypothesized that drug repositioning, facilitated by pan-cancer analyses, could lead to the identification of effective treatment strategies for these cancers.  \nResults  \nWe performed a comprehensive gene expression profiling of six major digestive system cancer types using The Cancer Genome Atlas data. Through integrative omics analysis, we identified 9,978 shared differentially expressed genes (DEGs) between colorectal cancer (CRC) and liver hepatocellular carcinoma (LIHC) . Functional enrichment analysis revealed nine common Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, with Cell Cycle being a significant shared pathway. Protein-protein interaction (PPI) network analysis identified core genes within these pathways, including CCNE1, CHEK1, NXF1, NCBP2, and RPS27A. A Connectivity Map (CMap) analysis matched 1,147 small molecules, leading to the identification of Amonafide and BX795 as top candidates. These two drugs were validated and shown to inhibit the proliferation and migration of CRC (HT-29) and LIHC (HepG2) cells and induce cell cycle arrest and apoptosis.  \nPLOS One | [https://doi.org/10.1371/journal.pone.0325700](https://doi.org/10.1371/journal.pone.0325700) June 16, 2025 1 / 16  \nand reproduction in any medium, provided the original author and source are credited.  \nData availability statement: The Cancer Genome Atlas (TCGA) ([https://portal.gdc](https://portal.gdc). [cancer.gov/](cancer.gov/)) database was explored to obtain transcriptomic data for 6 types of digestive system cancers. A total of 316 samples were obtained, including 8 pairs of cholangiocarcinoma (CHOL), 50 pairs of colorectal cancer (CRC, including both colon and rectal adenocarcinoma (COAD/READ)), 13 pairs of esophageal carcinoma (ESCA), 50 pairs of liver hepatocellular carcinoma (LIHC), 4 pairs of pancreatic adenocarcinoma (PAAD), and 33 pairs of st","cbCaispIldLhH4L6","https://ap.wps.com/l/cbCaispIldLhH4L6","pdf",1510094,16,"English","# Abstract\n## Background\n## Results\n## Data availability statement\n## Funding and competing interests\n## Abbreviation\n## Conclusion\n## Background","[{\"question\":\"What cancers are included in the pan-cancer analysis in this study?\",\"answer\":\"The study covers six digestive system cancer types: cholangiocarcinoma, colorectal cancer, esophageal carcinoma, liver hepatocellular carcinoma, pancreatic adenocarcinoma, and stomach adenocarcinoma.\"},{\"question\":\"How were shared molecular targets identified across digestive system cancers?\",\"answer\":\"Shared differentially expressed genes were derived using TCGA gene expression profiling, followed by integrative omics analyses including functional enrichment and protein-protein interaction network analysis.\"},{\"question\":\"What drugs were highlighted as potential therapeutics, and how were they tested?\",\"answer\":\"A Connectivity Map analysis prioritized amonafide and BX795. The drugs were validated to inhibit proliferation and migration of CRC (HT-29) and LIHC (HepG2) cells and to induce cell-cycle arrest and apoptosis.\"}]","Drug repositioning for pan-cancers of the digestive system - Identification of amonafide and BX795 as potential therapeutics via integrative Omics analysis | PDF",1790162694,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/47d9e934dcb38ca1a0db77c2258de2b7.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7978885f9bbc376735580e180615e239.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c32e08a8a56642a3eb46a0c639318b3c.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd2119d62bfb435c33d3ad51ebf24f16.webp",980,1268]